Efficacy of Definitive Radiotherapy for Patients with Clinical Stage IIIB or IIIC Lung Adenocarcinoma and Epidermal Growth Factor Receptor (EGFR) Mutations Treated Using First- or Second-Generation EGFR Tyrosine Kinase Inhibitors

Table 4

Characteristics of patients included in the third supplementary analysis.

		RT group (n = 8)		Non-RT group (n = 42)		Standardized difference^†
		Number or mean (SD)^†	(%)^†	Number or mean (SD)^†	(%)^†	Before PSW	After PSW
Age (years)		69.13 (6.66)		65.21 (5.83)		0.624	≈0
Sex	Female	4	(50)	31	(74)	0.506	≈0
	Male	4	(50)	11	(26)
Residency	Non-northern	5	(62)	33	(79)	0.358	≈0
	Northern	3	(38)	9	(21)
Comorbidity	<1	‡	‡	‡	‡	0.501	≈0
	≥1	‡	‡	‡	‡
BMI (kg/m^2)		23.53 (3.15)		24.35 (4.33)		0.217	≈0
Social-economic status	Minimum wage or lower	‡	‡	‡	‡	0.285	≈0
	Higher	‡	‡	‡	‡
Smoking	No	‡	‡	‡	‡	0.144	≈0
	Yes	‡	‡	‡	‡
Clinical T-stage	T1–T2	‡	‡	‡	‡	0.133	≈0
	T3–T4	‡	‡	‡	‡
Clinical N-stage	N0–N2	4	(50)	13	(31)	0.133	≈0
	N3	4	(50)	29	(69)
Tumor size (mm)		52.38 (22.93)		42.71 (19.87)		0.450	≈0
ECOG PS	0-1	‡	‡	‡	‡	0.501	≈0
	2	‡	‡	‡	‡

BMI, body mass index; ECOG PS, eastern cooperative oncology group performance status; PS, propensity score; RT, radiotherapy; SD, standard deviation. ^†Rounded. ^‡The exact numbers are not reported because of a health and welfare data science center (HWDC) database center policy to avoid numbers ≤2 in single cells.